NasdaqGM:TVTXBiotechs
A Fresh Valuation Look at Travere Therapeutics (TVTX) After FDA Nod and Promising Clinical Results
If you own shares of Travere Therapeutics (TVTX) or are considering a position, this week’s twin updates could be your cue to take a closer look. Travere announced that the FDA approved changes to FILSPARI’s monitoring requirements for its IgA nephropathy therapy, easing a major patient burden. At the same time, the company shared promising long-term clinical data for its experimental enzyme therapy, pegtibatinase, in classical homocystinuria, with meaningful reductions in key disease...